Skip to main content

Market Overview

Alkermes Spikes 40% After Positive Data From Depression Treatment Trial

Alkermes Spikes 40% After Positive Data From Depression Treatment Trial

Shares of Alkermes Plc (NASDAQ: ALKS) are trading up more than 40 percent in Thursday’s after-hours session, after the company announced positive topline results from its late-stage clinical study of ALKS 5461 for the treatment of depression.

According to data out of FORWARD-5, the company’s third phase 3 efficacy study, ALKS 5461 considerably reduced the symptoms seen in patients with major depression disorder, compared to a placebo.

Based on these results, the company said it plans to “move forward rapidly to meet with the FDA to determine the appropriate next steps toward a regulatory submission for ALKS 5461.”

“ALKS 5461 is being developed as an add-on treatment for patients with depression not controlled by currently approved drugs. The pill had been touted by Alkermes as a potential blockbuster and an important growth driver based on promising results from a mid-stage study,” TheStreet's Adam Feuerstein explained.

Shares traded recently at $61.28, up 41 percent.


Related Articles (ALKS)

View Comments and Join the Discussion!

Posted-In: Biotech News FDA After-Hours Center Movers General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at